NR0B2 and PPARG

Data Source:
HPRD (in vivo)

		NR0B2	PPARG
Description		nuclear receptor subfamily 0 group B member 2	peroxisome proliferator activated receptor gamma
Image
GO Annotations	Cellular Component	Chromatin Nucleus Nucleoplasm Cytoplasm Protein-containing Complex	Chromatin Nucleus Nucleoplasm Cytosol Intracellular Membrane-bounded Organelle Receptor Complex Perinuclear Region Of Cytoplasm RNA Polymerase II Transcription Regulator Complex
	Molecular Function	Transcription Corepressor Activity Protein Binding Transcription Factor Binding Protein Domain Specific Binding Protein Homodimerization Activity Peroxisome Proliferator Activated Receptor Binding Protein-containing Complex Binding Retinoid X Receptor Binding Thyroid Hormone Receptor Binding Transcription Regulator Inhibitor Activity	Transcription Regulatory Region Sequence-specific DNA Binding RNA Polymerase II Cis-regulatory Region Sequence-specific DNA Binding DNA-binding Transcription Factor Activity, RNA Polymerase II-specific RNA Polymerase II Repressing Transcription Factor Binding DNA-binding Transcription Repressor Activity, RNA Polymerase II-specific DNA Binding Chromatin Binding Double-stranded DNA Binding DNA-binding Transcription Factor Activity Nuclear Receptor Activity Prostaglandin Receptor Activity Protein Binding Protein C-terminus Binding Transcription Factor Binding Zinc Ion Binding Enzyme Binding Protein Phosphatase Binding Estrogen Receptor Binding Activating Transcription Factor Binding Peptide Binding Identical Protein Binding Sequence-specific DNA Binding Protein Self-association Retinoid X Receptor Binding Arachidonic Acid Binding DNA Binding Domain Binding LBD Domain Binding Alpha-actinin Binding E-box Binding
	Biological Process	Negative Regulation Of Transcription By RNA Polymerase II Transcription Initiation From RNA Polymerase II Promoter Notch Signaling Pathway Circadian Rhythm Cholesterol Metabolic Process Response To Glucose Positive Regulation Of Gene Expression Negative Regulation Of Gene Expression Response To Organic Cyclic Compound Bile Acid And Bile Salt Transport Animal Organ Regeneration Positive Regulation Of Insulin Secretion Circadian Regulation Of Gene Expression Negative Regulation Of DNA-binding Transcription Factor Activity Response To Ethanol Negative Regulation Of Transcription, DNA-templated Positive Regulation Of Transcription, DNA-templated	Negative Regulation Of Transcription By RNA Polymerase II Placenta Development Negative Regulation Of Acute Inflammatory Response Regulation Of Transcription By RNA Polymerase II Transcription Initiation From RNA Polymerase II Promoter Lipid Metabolic Process Fatty Acid Metabolic Process Activation Of Cysteine-type Endopeptidase Activity Involved In Apoptotic Process Signal Transduction G Protein-coupled Receptor Signaling Pathway Heart Development Response To Nutrient Regulation Of Blood Pressure Response To Cold Response To Mechanical Stimulus Hormone-mediated Signaling Pathway Macrophage Derived Foam Cell Differentiation Negative Regulation Of Macrophage Derived Foam Cell Differentiation Negative Regulation Of Cholesterol Storage Negative Regulation Of Sequestering Of Triglyceride Long-chain Fatty Acid Transport Negative Regulation Of Angiogenesis Regulation Of Lipid Metabolic Process Fatty Acid Oxidation Cell Differentiation Monocyte Differentiation Negative Regulation Of Cell Growth Negative Regulation Of BMP Signaling Pathway Epithelial Cell Differentiation Response To Caffeine Animal Organ Regeneration Cellular Response To Insulin Stimulus Negative Regulation Of Collagen Biosynthetic Process Response To Vitamin A Response To Lipid Peroxisome Proliferator Activated Receptor Signaling Pathway Response To Immobilization Stress Response To Drug Glucose Homeostasis Response To Starvation Regulation Of Circadian Rhythm Lipoprotein Transport Positive Regulation Of DNA Binding Negative Regulation Of Blood Vessel Endothelial Cell Migration Response To Estrogen Innate Immune Response Cell Fate Commitment Positive Regulation Of Fat Cell Differentiation Negative Regulation Of Osteoblast Differentiation Negative Regulation Of Transcription, DNA-templated Positive Regulation Of Transcription, DNA-templated Positive Regulation Of Fatty Acid Metabolic Process Positive Regulation Of Transcription By RNA Polymerase II Positive Regulation Of Fatty Acid Oxidation Retinoic Acid Receptor Signaling Pathway Cell Maturation Rhythmic Process Negative Regulation Of Smooth Muscle Cell Proliferation Positive Regulation Of Oligodendrocyte Differentiation Negative Regulation Of Inflammatory Response White Fat Cell Differentiation Positive Regulation Of DNA-binding Transcription Factor Activity Negative Regulation Of Telomerase Activity Lipid Homeostasis Positive Regulation Of Phagocytosis, Engulfment Negative Regulation Of Interferon-gamma-mediated Signaling Pathway Regulation Of Cholesterol Transporter Activity Negative Regulation Of Gene Silencing By MiRNA Cellular Response To Retinoic Acid Cellular Response To Vitamin E Cellular Response To Prostaglandin E Stimulus Cellular Response To Low-density Lipoprotein Particle Stimulus Cellular Response To Hyperoxia Response To Metformin Positive Regulation Of Pri-miRNA Transcription By RNA Polymerase II Negative Regulation Of Vascular Associated Smooth Muscle Cell Proliferation Positive Regulation Of Vascular Associated Smooth Muscle Cell Apoptotic Process Negative Regulation Of Vascular Endothelial Cell Proliferation Positive Regulation Of Low-density Lipoprotein Receptor Activity Negative Regulation Of Pancreatic Stellate Cell Proliferation Negative Regulation Of Signaling Receptor Activity
Pathways		Nuclear Receptor transcription pathway	PPARA activates gene expression Transcriptional regulation of white adipocyte differentiation Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Regulation of PTEN gene transcription Regulation of PTEN gene transcription MECP2 regulates transcription factors
Drugs			alpha-Linolenic acid Icosapent Troglitazone Mesalazine Valproic acid Indomethacin Rosiglitazone Fenoprofen Nateglinide Sulfasalazine Clofazimine Repaglinide Telmisartan Balsalazide Ibuprofen Glipizide Amiodarone Pioglitazone Mitiglinide Bezafibrate Flufenamic acid Resveratrol Phthalic Acid Capric acid Doconexent Oleic Acid (S)-3-(4-(2-Carbazol-9-Yl-Ethoxy)-Phenyl)-2-Ethoxy-Propionic Acid 2-{5-[3-(6-BENZOYL-1-PROPYLNAPHTHALEN-2-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID Reglitazar Elafibranor AMG-131 CLX-0921 Muraglitazar Ertiprotafib Ragaglitazar Tesaglitazar (2S)-3-(1-{[2-(2-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL]METHYL}-1H-INDOL-5-YL)-2-ETHOXYPROPANOIC ACID (9Z,11E,13S)-13-hydroxyoctadeca-9,11-dienoic acid 2-{5-[3-(7-PROPYL-3-TRIFLUOROMETHYLBENZO[D]ISOXAZOL-6-YLOXY)PROPOXY]INDOL-1-YL}ETHANOIC ACID (4S,5E,7Z,10Z,13Z,16Z,19Z)-4-hydroxydocosa-5,7,10,13,16,19-hexaenoic acid (5R,6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoic acid (8E,10S,12Z)-10-hydroxy-6-oxooctadeca-8,12-dienoic acid (8R,9Z,12Z)-8-hydroxy-6-oxooctadeca-9,12-dienoic acid 9(S)-HODE difluoro(5-{2-[(5-octyl-1H-pyrrol-2-yl-kappaN)methylidene]-2H-pyrrol-5-yl-kappaN}pentanoato)boron (2S)-2-ETHOXY-3-{4-[2-(10H-PHENOXAZIN-10-YL)ETHOXY]PHENYL}PROPANOIC ACID 3-(5-methoxy-1H-indol-3-yl)propanoic acid Indeglitazar (2S)-2-(4-ethylphenoxy)-3-phenylpropanoic acid 2-chloro-5-nitro-N-phenylbenzamide (2S)-2-(biphenyl-4-yloxy)-3-phenylpropanoic acid 3-[5-(2-nitropent-1-en-1-yl)furan-2-yl]benzoic acid 2-[(2,4-DICHLOROBENZOYL)AMINO]-5-(PYRIMIDIN-2-YLOXY)BENZOIC ACID (5E,14E)-11-oxoprosta-5,9,12,14-tetraen-1-oic acid 3-FLUORO-N-[1-(4-FLUOROPHENYL)-3-(2-THIENYL)-1H-PYRAZOL-5-YL]BENZENESULFONAMIDE Triclosan (2S)-2-(4-chlorophenoxy)-3-phenylpropanoic acid Aleglitazar Clinofibrate Cannabidiol Lobeglitazone Ciglitazone Dexibuprofen Omega-3 fatty acids Curcumin Arhalofenate Isoflavone Naveglitazar Fenofibric acid Fish oil Medical Cannabis Nabiximols Darglitazone Curcumin sulfate
Diseases			Type II diabetes mellitus Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Thyroid cancer
GWAS		Chronic obstructive pulmonary disease or high blood pressure (pleiotropy) ( 30940143) HDL cholesterol ( 24097068) LDL cholesterol ( 24097068) Triglycerides ( 24097068)	Adult body size ( 32376654) Apolipoprotein A1 levels ( 32203549) Apolipoprotein B levels ( 32203549) Arterial stiffness index ( 31235810) Body mass index ( 28892062 25673413 29273807) Cholesterol, total ( 25961943) Drug-induced liver injury ( 22968431) Endometrial cancer ( 30093612) Endometrial cancer (endometrioid histology) ( 30093612) Eosinophil counts ( 32888494 27863252) Eosinophil percentage of granulocytes ( 27863252) Eosinophil percentage of white cells ( 32888494 27863252) Fasting blood insulin ( 25631608) Fasting blood insulin (BMI interaction) ( 22581228) Fasting blood insulin adjusted for BMI ( 25625282) Gut microbiota (functional units) ( 27694959) HDL cholesterol ( 30275531) HDL cholesterol levels ( 32203549) Heel bone mineral density ( 30598549) Hematocrit ( 32888494 27863252) Hemoglobin ( 32888494) Hemoglobin concentration ( 27863252) Hemoglobin levels ( 32327693) High density lipoprotein cholesterol levels ( 29403010) High light scatter reticulocyte count ( 32888494) Hip circumference adjusted for BMI ( 25673412) Idiopathic osteonecrosis of the femoral head ( 31135556) LDL cholesterol ( 25961943) LDL cholesterol levels ( 32203549 30698716) LDL cholesterol levels in current drinkers ( 30698716) LDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df) ( 30698716) LDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df) ( 30698716) Medication use (drugs used in diabetes) ( 31015401) Medication use (HMG CoA reductase inhibitors) ( 31015401) Medication use (thyroid preparations) ( 31015401) Modified Stumvoll Insulin Sensitivity Index (model adjusted for BMI) ( 27416945) Neutrophil percentage of granulocytes ( 27863252) Plasminogen activator inhibitor type 1 levels (PAI-1) ( 22990020) Platelet count ( 29403010) Platelet distribution width ( 32888494) Plateletcrit ( 32888494) Potassium levels ( 29403010) Red blood cell count ( 32888494) Red cell distribution width ( 32888494) Sexual dimorphism in anthropometric traits ( 23754948) Systemic lupus erythematosus ( 28714469) Thyroid stimulating hormone levels ( 32769997) Triglyceride levels ( 32203549 32154731) Type 2 diabetes ( 22885922 18372903 24509480 30054458 29358691 30297969 29632382 31118516 32499647 20581827 17463246 30718926 17463248 17463249 28869590) Type 2 diabetes (adjusted for BMI) ( 29632382) Waist circumference ( 31453325) Waist circumference variance ( 31453325) Waist-hip ratio ( 25673412) Waist-to-hip ratio adjusted for BMI ( 26426971) Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour) ( 28443625) Waist-to-hip ratio adjusted for BMI (age <50) ( 26426971) Waist-to-hip ratio adjusted for BMI (age >50) ( 26426971) Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction) ( 28448500) Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction) ( 28443625) Waist-to-hip ratio adjusted for BMI in active individuals ( 28448500) Waist-to-hip ratio adjusted for BMI in non-smokers ( 28443625) Waist-to-hip ratio adjusted for BMI x sex x age interaction (4df test) ( 26426971) Waist-to-hip ratio adjusted for body mass index ( 25673412 28448500) Youthful appearance (self-reported) ( 32339537)
Interacting Genes		51 interacting genes: AR CHRD CIDEC DDX20 EID1 ESR1 ESR2 ESRRA ESRRG FN1 GPS2 GPSM3 HDAC3 HDAC6 HNF4A HNF4G HNRNPA1 ID2 IL3RA NCOA3 NEUROD1 NR1H2 NR1H3 NR1I2 NR1I3 NR3C1 NR5A2 PAX9 PEF1 PLSCR1 POLR2A PPARD PPARG RARA RARG RBP5 RNF31 RXRA RXRB RXRG SMAD4 SMARCA2 SMARCB1 SMARCE1 SNW1 THRA TP53 VDR XBP1 ZAP70 ZMYND10	115 interacting genes: ADCY4 ALOX15B ANP32A APP BCAS2 BRD8 CDC34 CDK5 CEP350 CNOT1 COPS5 CREBBP DNTTIP2 EDF1 EGFR EP300 ESRRA FABP1 FHOD1 FOXO1 GADD45B GADD45G GATA5 GRIP1 HDAC1 HDAC3 HDAC4 HELZ2 HMGA1 IGFBP3 IKBKB JAZF1 JMJD1C JUN JUND KAT2A KAT5 KCTD13 KIF11 KIF1A KLF5 LMO4 LRIF1 MAFF MAP2K1 MAPK1 MAPK8 MAPK9 MED1 MED24 MFHAS1 MIF4GD MSX2 MUC1 NCOA1 NCOA2 NCOA3 NCOA4 NCOA6 NCOR1 NCOR2 NFE2L2 NFE2L3 NFKB1 NFKBIB NR0B1 NR0B2 NR1H2 NR1H3 NR2E3 NR4A1 NR4A2 NRIP1 NSD1 PAK4 PDIA2 PHB2 PML POU1F1 PPARGC1A PPM1B PRKCA RAD54L2 RANBP9 RARA RB1 RELA ROBO4 RXRA RXRB RXRG SERPINH1 SFPQ SIRT1 SMARCD3 SRSF1 STAT6 STUB1 SVIL SYT1 TFAP2A TNP1 TRIM24 TRIP4 UBC UBE2I USP7 VDR ZBTB20 ZBTB3 ZBTB5 ZBTB9 ZNF496 ZNHIT3 ZSCAN1
Entrez ID		8431	5468
HPRD ID		05219	03288
Ensembl ID		ENSG00000131910	ENSG00000132170
Uniprot IDs		Q15466	A0A494C1F9 D2KUA6 E9PFV2 E9PFX5 P37231
PDB IDs		1YUC 2Q3Y 2Z4J 4DOR 4ONI 5UFS 6W9M	1FM6 1FM9 1I7I 1K74 1KNU 1NYX 1PRG 1RDT 1WM0 1ZEO 1ZGY 2ATH 2F4B 2FVJ 2G0G 2G0H 2GTK 2HFP 2HWQ 2HWR 2I4J 2I4P 2I4Z 2OM9 2P4Y 2POB 2PRG 2Q59 2Q5P 2Q5S 2Q61 2Q6R 2Q6S 2Q8S 2QMV 2VSR 2VST 2VV0 2VV1 2VV2 2VV3 2VV4 2XKW 2YFE 2ZK0 2ZK1 2ZK2 2ZK3 2ZK4 2ZK5 2ZK6 2ZNO 2ZVT 3ADS 3ADT 3ADU 3ADV 3ADW 3ADX 3AN3 3AN4 3B0Q 3B0R 3B1M 3B3K 3BC5 3CDP 3CDS 3CS8 3CWD 3D6D 3DZU 3DZY 3E00 3ET0 3ET3 3FEJ 3FUR 3G9E 3GBK 3H0A 3HO0 3HOD 3IA6 3K8S 3KMG 3LMP 3NOA 3OSI 3OSW 3PBA 3PO9 3PRG 3QT0 3R5N 3R8A 3R8I 3S9S 3SZ1 3T03 3TY0 3U9Q 3V9T 3V9V 3V9Y 3VJH 3VJI 3VN2 3VSO 3VSP 3WJ4 3WJ5 3WMH 3X1H 3X1I 4A4V 4A4W 4CI5 4E4K 4E4Q 4EM9 4EMA 4F9M 4FGY 4HEE 4JAZ 4JL4 4L96 4L98 4O8F 4OJ4 4PRG 4PVU 4PWL 4R06 4R2U 4R6S 4XLD 4XTA 4XUH 4XUM 4Y29 4YT1 5AZV 5DSH 5DV3 5DV6 5DV8 5DVC 5DWL 5F9B 5GTN 5GTO 5GTP 5HZC 5JI0 5LSG 5TTO 5TWO 5U5L 5UGM 5WQX 5WR0 5WR1 5Y2O 5Y2T 5YCN 5YCP 5Z5S 5Z6S 6AD9 6AN1 6AUG 6AVI 6C1I 6C5Q 6C5T 6D3E 6D8X 6D94 6DBH 6DCU 6DGL 6DGO 6DGP 6DGQ 6DGR 6DH9 6DHA 6E5A 6ENQ 6F2L 6FZF 6FZG 6FZJ 6FZP 6FZY 6ICJ 6IJR 6IJS 6ILQ 6IZM 6IZN 6JEY 6JF0 6JQ7 6K0T 6KTM 6KTN 6L89 6L8B 6MCZ 6MD0 6MD1 6MD2 6MD4 6MS7 6O67 6O68 6ONI 6ONJ 6PDZ 6QJ5 6T6B 6T9C 6TSG 6Y3U 7AHJ
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?